Mircera and Veltassa led to a sales miss in FY20. Although Ferinject witnessed a strong rebound with the loosening of COVID-19 restrictions, it lost momentum again towards the end of the year. The lower proportion of high-margin drugs in the sales mix weighed on profitability as well. Interestingly, Vifor has made good progress on the business development and R&D front in the last few quarters and anticipates low-to-mid-single sales growth for FY21. More licensing/ bolt-on deals are also on the ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
COVID-19 weighs on FY20 performance; new drug launches on the cards
- Published:
03 Mar 2021 -
Author:
Sumit Sayal -
Pages:
5
Mircera and Veltassa led to a sales miss in FY20. Although Ferinject witnessed a strong rebound with the loosening of COVID-19 restrictions, it lost momentum again towards the end of the year. The lower proportion of high-margin drugs in the sales mix weighed on profitability as well. Interestingly, Vifor has made good progress on the business development and R&D front in the last few quarters and anticipates low-to-mid-single sales growth for FY21. More licensing/ bolt-on deals are also on the ....